MANIFEST-2: Pelabresib in Myelofibrosis: MOA, Study Design, and Spleen Volume Reduction
Panelists discuss the MANIFEST-2 trial of pelabresib in myelofibrosis, focusing on its mechanism of action (MOA), study design, and impact on spleen volume reduction.
Video Player is loading.
EP: 1.Myelofibrosis: Background, Risk Stratification, and Treatment Decision-Making
EP: 2.Approved and Investigational Agents for Myelofibrosis
EP: 3.Disease Modification Strategies and Unmet Needs in Myelofibrosis
Now Viewing
EP: 4.MANIFEST-2: Pelabresib in Myelofibrosis: MOA, Study Design, and Spleen Volume Reduction
EP: 5.Disease- Modifying Biomarker Data in the MANIFEST-2 Study Investigating Pelabresib
EP: 6.Safety Profile of the Pelabresib and Ruxolitinib Combination in Myelofibrosis
EP: 7.Pelabresib in MPNs: Immune Profiles of Responders vs. Non-responders
Recent Videos
CAR T vs Bispecifics: Expanding CAR T Reach in B-Cell Malignancies
Real-World Use, Outpatient Dosing and Transitions of Care in Academic and Community Settings
A Review of Outpatient Step-Up Dosing for Talquetamab in R/R MM
PERSEUS Trial: MRD Negativity
PERSEUS Trial: Design/Baseline Characteristics
Treatment Overview of Transplant-Eligible Newly Diagnosed Multiple Myeloma
Understanding ICANS Management With CAR T: Low-Grade Events With High Resolution Rates
CEPHEUS Trial: Adverse Events
CRS Management Insights With Liso-Cel: Comprehensive Analysis From Real-World Data in 1579 Patients and Implications for Safe Clinical Practice
Talquetamab in R/R MM: Managing GPRC5D-direced AEs, Prophylaxis, and New Safety Signals
Related Content
